Brief: Botanix Pharmaceuticals Announces Submission Of FDA New Drug Application For Sofpironium Bromide
26/09/2022 02:28
Sept 26 (Reuters) - Botanix Pharmaceuticals Ltd
BOT.AX :
* SUBMISSION OF FDA NEW DRUG APPLICATION FOR SOFPIRONIUM
BROMIDE
Source text for Eikon: ID:nASX4jlCp7
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million